Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26675163
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26675163
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Gastrointest+Tumors
2013 ; 1
(1
): 33-40
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Pancreatic Cancer: Clinical Significance of Biomarkers
#MMPMID26675163
Ohuchida K
; Ohtsuka T
; Mizumoto K
; Hashizume M
; Tanaka M
Gastrointest Tumors
2013[Sep]; 1
(1
): 33-40
PMID26675163
show ga
BACKGROUND: Improvement in the prognosis of patients with pancreatic cancer,
novel effective screening and diagnostic strategies and treatments are needed.
Recent advances in the understanding of pancreatic carcinogenesis and tumor
microenvironment have allowed identification of biomarkers for screening,
diagnosis and prediction of cancer treatments, including novel therapies
targeting specific cancer or stromal cell subpopulations. Personalized therapy in
pancreatic cancer is also promising as several drugs such as S1, capecitabine and
gemcitabine reportedly have significant therapeutic effects. Predictive markers
are thus needed to select patients most likely to benefit from therapies based on
gemcitabine or other drugs. SUMMARY: We review the clinical significance of
promising screening, diagnostic, predictive and prognostic biomarkers based on
genetic and epigenetic alterations and microRNA abnormalities in pancreatic
cancer. We also review new types of biomarkers based on stromal cells, such as
pancreatic stellate cells, in the microenvironment of pancreatic cancer.
free
free
free
